Doxorubicin

Across CCLE and GDSC cell-line panels, response to Doxorubicin is significantly associated with the response to other drugs of multiple drugs, with KIDNEY cell lines showing a particularly strong set of associations.

The most reproducible Doxorubicin response-associated drugs across cancer lineages are Mitomycin-C, Epothilone B, and Etoposide, each associated with drug response in up to 20 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, Doxorubicin response versus Mitomycin-C response to other drugs in KIDNEY (Pearson r = 0.71).

Response to other drugs biomarkers of Doxorubicin response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner drug	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
KIDNEY	Mitomycin-C →	+1.666	+1.279	.002	.010	3	20
URINARY_TRACT	Epothilone B →	+1.612	+1.162	<.001	<.001	3	20
LIVER	Etoposide →	+1.987	+1.497	<.001	<.001	3	19
LUNG_NSCLC_LUSC	GSK-J4 →	+1.344	+0.904	.003	.001	3	19
BLOOD_Myeloma	PLK_6522 →	+1.494	+1.062	.027	.007	3	19
BONE	PARP_0108 →	+1.407	+0.754	<.001	<.001	3	19

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Doxorubicin response vs Mitomycin-C — KIDNEY

Explore this scatter interactively →